CDR2 and gastric adenocarcinoma: The two individuals who died at 6 and 12 months after the initial diagnosis (15%), were patient #9 with anti-Hu and small-cell lung cancer and patient #7 with anti-Yo and gastric adenocarcinoma, respectively (Table 3).